A promising medication , retatrutide, is creating considerable excitement within the Oz weight loss community. Developed by Lilly , this twin GIP and GLP-1 receiver appears to provide more significant benefits than existing therapies. Preliminary scientific trials have shown remarkable decreases in physical mass, raising the potential for a innovat